Tolsura Capsule, Gelatin Coated
NDC Package 51862-462-60
Package Information
Tolsura (itraconazole) capsules is itraconazole is used to treat a variety of fungal infections. This formulation utilizes a capsule, gelatin coated delivery system. Marketed by Mayne Pharma Commercial Llc, this product is identified by NDC 51862-462 and is authorized under FDA application NDA208901.
Identification & Billing
- RxCUI: 2106642 - itraconazole 65 MG Oral Capsule
- RxCUI: 2106642 - ICNZ 65 MG Oral Capsule
- RxCUI: 2106648 - TOLSURA 65 MG Oral Capsule
- RxCUI: 2106648 - itraconazole 65 MG Oral Capsule [Tolsura]
- RxCUI: 2106648 - ICNZ 65 MG Oral Capsule [Tolsura]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51862 - Mayne Pharma Commercial Llc
- 51862-462 - Tolsura
- 51862-462-60 - 60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC
- 51862-462 - Tolsura
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51862-462). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51862-462-60 identifies a specific commercial package of 60 capsule, gelatin coated in 1 bottle, plastic of Tolsura, a human prescription drug labeled by Mayne Pharma Commercial Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This capsule, gelatin coated is formulated for oral use and contains itraconazole as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mayne Pharma Commercial Llc on December 11, 2018. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Itraconazole is used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals. It works by stopping the growth of fungi.
How is this Mayne Pharma Commercial Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51862046260. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.